trending Market Intelligence /marketintelligence/en/news-insights/trending/dPaRGgfrGXPWhUsrCwUjhw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Cellular Biomedicine seeks to raise $17.5M via common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Cellular Biomedicine seeks to raise $17.5M via common stock offering

Cellular Biomedicine Group Inc. priced an underwritten public offering of 1,029,412 common shares at $17 apiece to raise about $17.5 million in gross proceeds.

The biopharmaceutical company granted the underwriters an option to buy up to an additional 154,411 shares.

Cellular Biomedicine plans to use the net proceeds from this offering for preclinical studies, clinical trials, continued technology platform development, as well as for working capital and other general corporate purposes.

Cantor Fitzgerald & Co. and Robert W. Baird & Co. Inc. are acting as joint book-running managers for the offering.

New York-based Cellular Biomedicine is focused on the development of immunotherapies for cancer and stem cell therapies for degenerative diseases.